<DOC>
	<DOCNO>NCT01913405</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety BAX 855 severe hemophilia A previously treat ( PTP ) male , 12 65 year age undergoing elective surgical invasive procedure .</brief_summary>
	<brief_title>Phase 3 Efficacy Safety Study BAX 855 Severe Hemophilia A Patients Undergoing Surgical Procedures</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Participant require elective major minor surgical , dental invasive procedure ( e.g . biopsy , endoscopy ) . Participant and/or legal representative has/have provide sign informed consent . Participant severe hemophilia A ( Factor VIII ( FVIII ) level &lt; 1 % ) confirm central lab screening document FVIII activity level &lt; 1 % . Participant previously treat FVIII concentrate ≥150 document exposure day ( EDs ) . Participant currently receive prophylaxis ondemand therapy FVIII concentrate . Participant Karnofsky performance score ≥60 screening . Participant human immunodeficiency virus negative ( HIV ) ; HIV+ stable disease CD4+ count ≥200 cells/mm^3 , confirmed central laboratory screening . Participant Hepatitis C virus negative ( HCV ) antibody PCR testing ( positive , antibody titer confirm PCR ) , confirmed central laboratory screening ; HCV+ chronic stable hepatitis assess investigator . Participant willing able comply requirement study protocol . Participant detectable FVIII inhibitory antibody ( ≥0.4 Bethesda Unit ( BU ) use Nijmegen modification Bethesda assay ) screening determined central laboratory timepoint prior screen ( ≥0.4 BU use Nijmegen modification Bethesda assay ≥0.6 BU use Bethesda assay ) . History ongoing recent thrombotic disease , fibrinolysis disseminate intravascular coagulation ( DIC ) . Participant platelet count &lt; 100 x 10^9/L , confirm central laboratory screening . Participant severe renal impairment ( serum creatinine &gt; 2.0 mg/dL ) , confirmed central laboratory screening . Participant severe chronic hepatic dysfunction ( eg ≥5 X upper limit normal alanine aminotransferase ( ALT ) , confirmed central laboratory screening , document International Normalized Ratio ( INR ) &gt; 1.5 ) . Participant known hypersensitivity towards mouse hamster protein , polysorbate 80 PEG . Participant currently use recently ( &lt; 30 day ) use pegylated drug ( BAX 855 ) prior study participation schedule use drug trial participation . Participant currently participate another clinical drug ( BAX 855 ) device study use another investigational product device within 30 day prior study entry . Participant diagnosis inherit acquire hemostatic defect hemophilia A . Participant currently receive , schedule receive course study , immunomodulating drug ( eg , systemic corticosteroid agent dose equivalent hydrocortisone &gt; 10 mg/day , alpha interferon ) antiretroviral chemotherapy . Participant clinically significant medical , psychiatric , cognitive illness , recreational drug/alcohol use , opinion investigator , would affect participant safety compliance .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>